Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.iCo Therapeutics raises $1.14 million in financing
The company intends to use the net proceeds of the offering for general corporate purposes and working capital. All common shares issued in the private placement will be
The company intends to use the net proceeds of the offering for general corporate purposes and working capital. All common shares issued in the private placement will be
Cysteamine is currently approved by the FDA and European Medicines Agency to treat nephropathic cystinosis, a rare lysosomal storage disease. Preclinical results suggest that cysteamine has neuroprotective effects
The invention addresses the field of dry powder inhalers, and more specifically the drug containment systems (DCS) necessary for containment, protection and delivery of dry powder medicaments. Materials,
The grant, from the National Institute of Allergy and Infectious Diseases under the National Institutes of Health (NIH), will help Micronics determine whether its rapid nucleic acid test
This patent protects Cytori’s key device technology, which processes adult stem and regenerative cells from adipose tissue at the patient’s bedside. The new US patent is a central
This first-in-man trial is a prospective, multi-center, single-blind, randomized, controlled study using the Cinatra voclosporin-coated coronary stent system, which will be compared to Atrium’s Cinatra bare metal coronary
Under the agreement, TapImmune has the option to acquire three follow-on technologies developed at the University of British Columbia (UBC) that fall under the scope of the original
Both PharmaLink and Matrix Contract Research have been providing contract research services for biotechnology, pharmaceutical and device companies for approximately 10 years. The two companies have partnered together
Kardia said that the move provides a more comprehensive line of high performance products and services for cardiology. With this acquisition, Kardia expects to offer customers a complete
Zaleplon capsules are the generic version of King Pharmaceuticals’s Sonata capsules, which had US sales of approximately $88 million for the 12 months ended March 31, 2008, according